Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) in a report published on Friday. The firm currently has a $14.00 price target on the stock.

KPTI has been the topic of several other research reports. Wedbush reissued an outperform rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, March 13th. Zacks Investment Research downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a research note on Wednesday, March 8th. Jefferies Group LLC reissued a buy rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, March 3rd. Finally, Canaccord Genuity reissued a buy rating and issued a $20.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, March 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $13.76.

Karyopharm Therapeutics (NASDAQ:KPTI) traded up 2.03% during mid-day trading on Friday, hitting $10.58. The stock had a trading volume of 112,627 shares. The company’s market capitalization is $436.35 million. The stock’s 50-day moving average is $10.71 and its 200 day moving average is $9.69. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63.

Your IP Address:

Several hedge funds have recently added to or reduced their stakes in KPTI. Trexquant Investment LP bought a new stake in Karyopharm Therapeutics during the fourth quarter worth about $273,000. Citadel Advisors LLC bought a new stake in Karyopharm Therapeutics during the third quarter worth about $286,000. Baker BROS. Advisors LP bought a new stake in Karyopharm Therapeutics during the third quarter worth about $2,111,000. Piermont Capital Management Inc. bought a new stake in Karyopharm Therapeutics during the third quarter worth about $507,000. Finally, JPMorgan Chase & Co. increased its stake in Karyopharm Therapeutics by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 374,000 shares of the company’s stock worth $3,639,000 after buying an additional 12,021 shares in the last quarter. 56.97% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/karyopharm-therapeutics-kpti-buy-rating-reaffirmed-at-hc-wainwright/1709242.html

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *